iOnctura is a biopharmaceutical company focusing on novel therapeutics to modulate key culprits of immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors (eg PD/PD-L1) have shown remarkable effectiveness for some but not for all cancer patients. iOnctura aims to improve current immune checkpoint therapies by developing novel drugs with potential best-in-class safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology. Headquartered in Geneva, Switzerland, iOnctura was founded by M Ventures in June 2017.

Team Members
more about
Bauke Anninga
more about
Hakan Goker
Managing Director
Latest News Entry
iOnctura data at AACR demonstrates unique mechanism of action for clinical stage autotaxin inhibitor IOA-289

iOnctura has preclinical data that shows its autotaxin inhibitor IOA-289 both inhibits pancreatic cells directly and inhibits the cancerpromoting activity of secreted factors from Cancer-Associated Fibroblasts (CAFS)

iOnctura To Present Preclinical Data On Its Clinical Stage Autotaxin Inhibitor, IOA-289, At AACR

iOnctura SA will present preclinical data on its next-generation autotaxin inhibitor, IOA-289, at the annual meeting of the American Association for Cancer Research (AACR) taking place on April 8-13, 2022 in New Orleans, Louisiana.

iOnctura Appoints Industry Veteran Dr. Joanna Horobin as Chair
iOnctura Expands its Clinical Advisory Board

iOnctura SA announces the addition of new members to its Clinical Advisory Board (CAB)

iOnctura selected for an oral presentation at 2019 AACR Annual Meetin

iOnctura SA announced today that its abstract (abstract # 1781) “Preclinical development of a novel, highly selective PI3Kδ inhibitor" has been selected for an oral presentation at the American Association for Cancer Research Annual Meeting 2019.

iOnctura Announces Appointment of Leading International Scientific Advisory Board

iOnctura SA, a recently founded late stage preclinical immuno-oncology company, announced today the formation of an international Scientific Advisory Board (SAB).

all related news
all portfolio news